Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
Status:
RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo.
Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.